![Keun Chan Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Keun Chan Park
Sociétés | Poste | Début | Fin |
---|---|---|---|
Theromics, Inc.
![]() Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Directeur Technique/Scientifique/R&D | - | - |
Fondateur | - | - |
Historique de carrière de Keun Chan Park
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Theromics, Inc.
![]() Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Health Technology |
- Bourse
- Insiders
- Keun Chan Park
- Expérience